Cell News and Research

RSS

Gene therapy may help correct molecular flaws that cause brain disease

Neuroscientists have forged an unlikely molecular union as part of their fight against diseases of the brain and nervous system.

9 Jan 2010

SeraCare Life Sciences launches new products to aid discovery and development of drugs and diagnostics

SeraCare Life Sciences, Inc. announced today that the Company has added five new, differentiated products to its portfolio to meet the needs of SeraCare’s growing customer base in the life sciences industry.

9 Jan 2010

Los Alamos National Laboratory identifies 'Top 10 Laboratory science stories of 2009'

Los Alamos National Laboratory (www.lanl.gov) has identified the Top 10 Laboratory science stories of 2009 based on global viewership of online media content and major programmatic milestones.

9 Jan 2010

Nominations open for 2010 National Courage Award

Nominations are now being accepted for the 2010 National Courage Award. Since 1980, Minnesota-based Courage Center has presented the National Courage Award, which recognizes an individual's contributions to the health, welfare and rehabilitation of people with disabilities.

9 Jan 2010

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the “Advances in Biopharmaceuticals” Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.

9 Jan 2010

Research determines and validates the efficacy of T category in IASLC's Staging Manual

Research released in the January 2010 issue of the Journal of Thoracic Oncology sought to determine and validate the efficacy of the recent reclassification of the T category in the IASLC's Staging Manual in Thoracic Oncology.

9 Jan 2010

Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development

Acetylon Pharmaceuticals, Inc. announced today that it has closed on a $2 million investment from a new undisclosed private investor to bring its total financing to $9.25 million. This new investment will convert to stock in the next substantial round of preferred equity financing.

9 Jan 2010

Time frame for parents to begin toilet training lessons for children

Researchers at The Bristol-Myers Squibb Children's Hospital (BMSCH) at Robert Wood Johnson University Hospital (RWJUH) and UMDNJ-Robert Wood Johnson Medical School (UMDNJ-RWJMS) have completed a study that pinpoints the period between 24 and 32 months of age as most effective time frame for parents to begin toilet training lessons with their children.

9 Jan 2010

UCF research opens a new exploratory path for Alzheimer's disease

Despite a massive global research effort, many basics of Alzheimer's disease onset remain elusive. This has hampered development of treatments effective during the earliest stages of the disease, when prevention is most likely.

9 Jan 2010

Scientific societies to hold Experimental Biology 2010 meeting

Six scientific societies announced they will hold their annual meeting, Experimental Biology (EB 2010; www.experimentalbiology.org), April 24-28, 2010 in Anaheim, CA. The societies are the American Association of Anatomists (AAA), American Physiological Society (APS), American Society for Biochemistry and Molecular Biology (ASBMB), American Society for Investigative Pathology (ASIP), American Society for Nutrition (ASN) and American Society for Pharmacology and Experimental Therapeutics (ASPET).

9 Jan 2010

Immune cells causes inflammation in thyroid-associated ophthalmopathy

A cell type that causes significant scarring in lung disease appears to have a similar effect in Graves' disease, University of Michigan Health System researchers have found. The cells, called fibrocytes, are present at a higher than normal frequency in patients with Graves' disease, according to a new study, the first to associate fibrocytes with this autoimmune disease.

9 Jan 2010

Fibrocytes associated with Graves' disease

9 Jan 2010

LFB completes conversion of all acquired preferred stock

GTC Biotherapeutics, Inc. announced that LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire Français du Fractionnement et des Biotechnologies S.A., Les Ulis, France) and a strategic shareholder in GTC, has converted the convertible preferred stock it previously purchased in November 2009 under the terms described in the financing agreements approved by GTC shareholders in July 2009 into a total of 5.3 million shares of common stock.

9 Jan 2010

Oxygen Biotherapeutics' common stock approved for listing on NASDAQ Capital Market

Oxygen Biotherapeutics, Inc. announced today that its common stock has been approved for listing on the NASDAQ Capital Market.

9 Jan 2010

ACT receives FDA notification regarding its embryonic stem cell trials for SMD

Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that it has received notification from the US Food and Drug Administration (FDA) that the Agency is currently drafting a response to the Company relating to the Investigational New Drug (IND) Application it filed in November seeking clearance to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD).

9 Jan 2010

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

University of Michigan researchers have identified the first biomarker of graft-versus-host disease of the skin. The discovery makes possible a simple blood test that should solve a treatment dilemma facing doctors with patients who frequently develop rashes after bone marrow transplants.

9 Jan 2010

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 “BRAF Inhibitor in Melanoma” (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.

9 Jan 2010

Jiangsu Government grants $1.8M for research and development of hUC-MSC technologies

The Jiangsu Government's Science and Technology Department has announced a $1.8 million grant - the Jiangsu Technological Achievements Transformational Grant - to support the research and development of human umbilical cord mesenchymal stem cell (hUC-MSC) technologies. The grant recipient and administrator, Shenzhen Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com ), is working with Jiangsu University and Nanjing University's Drum Tower Hospital to fulfill the grant's requirements.

9 Jan 2010

New stem cell therapies to feature at 5th Annual Stem Cell Summit in NYC

Six new stem cell therapies, all forecast to reach physicians in 2010, will be featured at the 5th Annual Stem Cell Summit on February 16 in New York City. These new therapies include allograft products, innovative forms of autologous stem cell technologies, and at least one FDA-approved stem cell drug. New studies showing rehydration of the disc nucleus, regeneration of new heart muscle and others are also on the agenda.

9 Jan 2010

Green Cross seeks regulatory approval for peramivir in S.Korea

BioCryst Pharmaceuticals, Inc. today announced that it has been informed by its partner, Green Cross Corp., that Green Cross has filed a New Drug Application (NDA) in South Korea to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza.

9 Jan 2010